Figure 2

Examination of the prognostic value of CysLT₁ and CysLT₂ protein expression in primary UM samples by manual pathology. (A) Representative cores from the UM patient TMA designated with a score of 1, 2, or 3 for CysLT₁ staining intensity. (B) Kaplan–Meier survival curve stratified based by high (red) or low (blue) CysLT₁ expression and death by metastatic melanoma (n = 51; Log-rank; p = 0.122; HR 2.04; 95% CI 0.81–5.12). (C) High expression of CysLT₁ (red) is significantly associated with reduced overall survival in primary UM patients (n =51; Log- rank; p = 0.034; HR 2.34; 95% CI 1.04–5.25) (D) Representative cores from the TMA designated with a score of 1, 2 or 3 for CysLT₂ staining intensity. (E). Kaplan–Meier survival curve stratified based by high (red) or low (blue) CysLT₂ expression and death by metastatic melanoma (n = 50; Log-rank; p = 0.341; HR 1.15, 95% CI 0.58–2.28). (F) Kaplan–Meier survival curve stratified based by high (red) or low (blue) CysLT₂ expression and death by any cause (n = 50; Log-rank; p = 0.697; HR 1.15; 95% CI 0.58–2.28). The median was used as the cut-off point for high versus low expression for all Kaplan–Meier survival curves. Number of events indicates the number of deaths due to metastatic melanoma (B,E). Number of events indicates the number of deaths due to any cause (C,F).